At the beginning of 2020, the Galician Scientific and Technical Advice Unit released a health technology assessment on irreversible electroporation (IRE) for the treatment of liver and pancreatic cancer that aimed to analyze its safety, effectiveness, considerations for use, and the economic, organizational, social, ethical, or legal aspects. The efficacy evidence of IRE in achieving complete ablation is insufficient. Safety evidence is also insufficient as it is unclear whether IRE is safer as the standard treatment.